• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于药物遗传学的精准医学模型（5SPM）在对神经阻滞剂治疗反应不佳的精神病患者中的应用。

Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy.

作者信息

Carrascal-Laso Lorena, Franco-Martín Manuel Ángel, García-Berrocal María Belén, Marcos-Vadillo Elena, Sánchez-Iglesias Santiago, Lorenzo Carolina, Sánchez-Martín Almudena, Ramos-Gallego Ignacio, García-Salgado M Jesús, Isidoro-García María

机构信息

Servicio de Psiquiatría, Hospital Provincial de Zamora, IBSAL, 49071 Zamora, Spain.

Farmacogenética y Medicina de Precisión, Servicio de Bioquímica, Hospital Universitario de Salamanca, IBSAL, 37007 Salamanca, Spain.

出版信息

J Pers Med. 2020 Dec 18;10(4):289. doi: 10.3390/jpm10040289.

DOI:10.3390/jpm10040289
PMID:33352925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7767089/
Abstract

Antipsychotics are the keystone of the treatment of severe and prolonged mental disorders. However, there are many risks associated with these drugs and not all patients undergo full therapeutic profit from them. The application of the 5 Step Precision Medicine model(5SPM), based on the analysis of the pharmacogenetic profile of each patient, could be a helpful tool to solve many of the problematics traditionally associated with the neuroleptic treatment. In order to solve this question, a cohort of psychotic patients that showed poor clinical evolution was analyzed. After evaluating the relationship between the prescribed treatment and pharmacogenetic profile of each patient, a great number of pharmacological interactions and pharmacogenetical conflicts were found. After reconsidering the treatment of the conflictive cases, patients showed a substantial reduction on mean daily doses and polytherapy cases, which may cause less risk of adverse effects, greater adherence, and a reduction on economic costs.

摘要

抗精神病药物是治疗严重和持续性精神障碍的关键。然而，这些药物存在许多风险，并非所有患者都能从它们那里获得充分的治疗益处。基于对每位患者药物遗传学特征的分析而应用的五步精准医学模型（5SPM），可能是解决许多传统上与抗精神病药物治疗相关问题的有用工具。为了解决这个问题，对一组临床进展不佳的精神病患者进行了分析。在评估了每位患者的规定治疗与药物遗传学特征之间的关系后，发现了大量的药物相互作用和药物遗传学冲突。在重新考虑冲突病例的治疗后，患者的平均每日剂量和联合治疗病例大幅减少，这可能会降低不良反应风险、提高依从性并降低经济成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88e0/7767089/fb8de53e2546/jpm-10-00289-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88e0/7767089/466643332b0e/jpm-10-00289-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88e0/7767089/4e5bd5a7b002/jpm-10-00289-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88e0/7767089/0f660f3b45f3/jpm-10-00289-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88e0/7767089/fb8de53e2546/jpm-10-00289-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88e0/7767089/466643332b0e/jpm-10-00289-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88e0/7767089/4e5bd5a7b002/jpm-10-00289-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88e0/7767089/0f660f3b45f3/jpm-10-00289-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88e0/7767089/fb8de53e2546/jpm-10-00289-g004.jpg

相似文献

1
Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy.基于药物遗传学的精准医学模型（5SPM）在对神经阻滞剂治疗反应不佳的精神病患者中的应用。
J Pers Med. 2020 Dec 18;10(4):289. doi: 10.3390/jpm10040289.
2
Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients.精准医学模式（5SPM）应用于精神病患者的经济影响
Pharmgenomics Pers Med. 2021 Aug 16;14:1015-1025. doi: 10.2147/PGPM.S320816. eCollection 2021.
3
Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a New Genotype.病例报告：应用于精准精神病学的药物遗传学可解释一名具有新基因型患者的治疗结果。
Front Psychiatry. 2022 Feb 25;12:830608. doi: 10.3389/fpsyt.2021.830608. eCollection 2021.
4
[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].[法国13家精神病医院抗精神病药物的处方模式]
Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7.
5
Ten Years of Experience Support Pharmacogenetic Testing to Guide Individualized Drug Therapy.十年经验支持药物遗传学检测以指导个体化药物治疗。
Pharmaceutics. 2022 Jan 11;14(1):160. doi: 10.3390/pharmaceutics14010160.
6
Pharmacogenetics and antipsychotic treatment response.药物遗传学与抗精神病药物治疗反应
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(1):53-67.
7
[Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].[在查尔斯·佩伦斯精神病院（波尔多）使用非典型抗精神病药物：对氨磺必利、氯氮平、奥氮平和利培酮处方实践的分析]
Encephale. 2002 Jul-Aug;28(4):329-42.
8
[Antipsychotics in bipolar disorders].[双相情感障碍中的抗精神病药物]
Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5.
9
Pharmacogenetics and outcome with antipsychotic drugs.药物遗传学与抗精神病药物的疗效
Dialogues Clin Neurosci. 2014 Dec;16(4):555-66. doi: 10.31887/DCNS.2014.16.4/jpouget.
10
[Pharmacogenetic aspects of the activity of cytochromes P450 in the metabolism of antipsychotics].[抗精神病药物代谢中细胞色素P450活性的药物遗传学方面]
Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(4):111-22.

引用本文的文献

1
Effect of , , and Variation on Antipsychotic Treatment Outcomes.[具体基因名称1]、[具体基因名称2]和[具体基因名称3]变异对抗精神病药物治疗结果的影响。 （你原文中三个“,”处应该是具体基因名称等内容，这里只是按格式补充完整以便理解）
Pharmaceuticals (Basel). 2025 Jun 14;18(6):892. doi: 10.3390/ph18060892.
2
How Plant Polyhydroxy Flavonoids Can Hinder the Metabolism of Cytochrome 3A4.植物多羟基黄酮如何阻碍细胞色素3A4的代谢。
Biomedicines. 2025 Mar 7;13(3):655. doi: 10.3390/biomedicines13030655.
3
A Comparison of Molecular Techniques for Improving the Methodology in the Laboratory of Pharmacogenetics.

本文引用的文献

1
Frequency, reasons, and factors associated with antipsychotic polypharmacy in Schizophrenia: A retrospective chart review in a tertiary hospital in India.精神分裂症中抗精神病药物联合使用的频率、原因及相关因素：印度一家三级医院的回顾性病历审查
Asian J Psychiatr. 2020 Jun;51:102022. doi: 10.1016/j.ajp.2020.102022. Epub 2020 Mar 27.
2
Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs.非典型抗精神病药物所致脂质紊乱相关基因多态性的研究进展
Front Pharmacol. 2020 Feb 4;10:1669. doi: 10.3389/fphar.2019.01669. eCollection 2019.
3
Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series.
分子技术在药物遗传学实验室方法学改进中的比较。
Int J Mol Sci. 2024 Oct 26;25(21):11505. doi: 10.3390/ijms252111505.
4
A systematic review of pharmacogenetic testing to guide antipsychotic treatment.一项关于指导抗精神病药物治疗的药物遗传学检测的系统评价。
Nat Ment Health. 2024;2(5):616-626. doi: 10.1038/s44220-024-00240-2. Epub 2024 Apr 17.
5
Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments.用于抗精神病药物治疗个体化的药物基因组学的临床效用与实施
Pharmaceutics. 2024 Feb 7;16(2):244. doi: 10.3390/pharmaceutics16020244.
6
Pharmacogenetics to Avoid Adverse Drug Reactions.避免药物不良反应的药物遗传学。
J Pers Med. 2022 Jan 26;12(2):159. doi: 10.3390/jpm12020159.
7
Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients.精准医学模式（5SPM）应用于精神病患者的经济影响
Pharmgenomics Pers Med. 2021 Aug 16;14:1015-1025. doi: 10.2147/PGPM.S320816. eCollection 2021.
精神分裂症患者从抗精神病药物联合治疗转换为单一治疗的有效性：病例系列
Clin Psychopharmacol Neurosci. 2020 Feb 29;18(1):159-163. doi: 10.9758/cpn.2020.18.1.159.
4
Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion?抗精神病药联合用药：肮脏的小秘密还是时尚？
Int J Neuropsychopharmacol. 2020 Feb 1;23(2):125-131. doi: 10.1093/ijnp/pyz068.
5
Cytochrome P450: genotype to phenotype.细胞色素P450：从基因型到表型
Xenobiotica. 2020 Jan;50(1):9-18. doi: 10.1080/00498254.2019.1648911. Epub 2019 Aug 14.
6
Association Between Antipsychotic Polypharmacy and Outcomes for People With Serious Mental Illness in England.抗精神病药联合用药与英国严重精神疾病患者结局的关联。
Psychiatr Serv. 2019 Aug 1;70(8):650-656. doi: 10.1176/appi.ps.201800504. Epub 2019 May 21.
7
Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.CYP2D6基因对利培酮和阿立哌唑暴露量及疗效的影响：一项回顾性队列研究。
Lancet Psychiatry. 2019 May;6(5):418-426. doi: 10.1016/S2215-0366(19)30088-4. Epub 2019 Apr 15.
8
A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia.来自西西伯利亚的精神分裂症患者的药物遗传学研究深入了解了抗精神病药引起的高催乳素血症的多巴胺能机制。
BMC Med Genet. 2019 Apr 9;20(Suppl 1):47. doi: 10.1186/s12881-019-0773-3.
9
Increasing antipsychotic dose for non response in schizophrenia.增加抗精神病药物剂量以应对精神分裂症无反应情况。
Cochrane Database Syst Rev. 2018 May 11;5(5):CD011883. doi: 10.1002/14651858.CD011883.pub2.
10
Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.CYP2D6、CYP3A4、CYP3A5 和 ABCB1 多态性对健康志愿者阿立哌唑药代动力学和安全性的影响。
Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):596-605. doi: 10.1111/bcpt.12960. Epub 2018 Feb 22.